Four ideas to bring drug substance and drug product manufacturing back to the U.S. In a recent Contract Pharma article, I shared the challenges of working with Chinese manufacturers and questioned if these growing concerns are sparking a shift back to U.S. manufacturing. When I wrote that article, the COVID-19 crisis was mostly confined to China, yet now it has become a full-blown pandemic, which the U.S. is in the throes of today.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile